what is known already: MNC is cheaper per cycle than COH but also less effective in terms of live birth rate (LBR). However, strict application of SET in COH cycles reduces effectiveness and up to three MNC cycles can be performed at the same costs as one COH cycle. study design, size, duration: The cost-effectiveness of MNC versus COH was evaluated in three simulated treatment scenarios: three cycles of MNC versus one cycle of COH with SET or double embryo transfer (DET) and subsequent transfer of cryopreserved embryos (Scenario 1); six cycles of MNC versus one cycle of COH with strictly SET and subsequent transfer of cryopreserved embryos (Scenario 2); six cycles of MNC with minimized medication (hCG ovulation trigger only) versus one cycle of COH with SET or DET and subsequent transfer of cryopreserved embryos (Scenario 3). We used baseline data obtained from two retrospective cohorts of consecutive patients (2005 -2008) undergoing MNC in the University Medical Center Groningen (n ¼ 499, maximum six cycles per patient) or their first COH cycle with subsequent transfer of cryopreserved embryos in the Academic Medical Center Amsterdam (n ¼ 392).
Introduction
During the last decades, clinicians have focussed on strategies to decrease costs and to avoid complications of IVF, such as multiple pregnancies and ovarian hyperstimulation syndrome (OHSS). These strategies include single embryo transfer (SET) instead of double embryo transfer (DET) and modifications of the hyperstimulation regimen, such as milder stimulation and natural cycle IVF (Rongieres-Bertrand et al., 1999; Hojgaard et al., 2001; Heijnen et al., 2004; Heijnen et al., 2007) . SET and DET have been the subject of many cost-effectiveness studies (Wolner-Hanssen and Rydhstroem 1998; De Sutter et al., 2002; Gerris et al., 2004; Lukassen et al., 2005; Fiddelers et al., 2006; Kjellberg et al., 2006; Fiddelers et al., 2009; Veleva et al., 2009; Aanesen et al., 2010; Scotland et al., 2011) , but only a few studies have been performed concerning the cost-effectiveness of IVF or ICSI in the natural cycle (Daya et al., 1995; Nargund et al., 2001; Aanesen et al., 2010) or IVF or ICSI in the modified natural cycle (MNC) with minimal stimulation (Pelinck et al., 2002; Sophonsritsuk et al., 2005; Aanesen et al., 2010) .
In the University Medical Center Groningen (UMCG), MNC has been offered on a routine basis since 2005 after extensive analysis of a multicentre cohort study (Pelinck et al., 2004 (Pelinck et al., , 2005 . MNC is based on the use of the single follicle that naturally develops to dominance, retrieval of a single oocyte and transfer of one embryo. MNC therefore practically eliminates the risk of multiple pregnancies and OHSS. Furthermore, medication costs per cycle are low. However, pregnancy rates per cycle in MNC are lower when compared with controlled ovarian hyperstimulation IVF or ICSI (COH). Cost saving by decreasing multiple pregnancy rates may be achieved by SET after COH as well, but studies show that pregnancy rates may be compromised if SET is applied rigorously (De Sutter et al., 2002; Fiddelers et al., 2006) . So far, no costeffectiveness studies have been performed comparing different strategies including MNC and COH, applying either strict SET in all patients or SET or DET depending on female age and embryo quality.
The research question for the present study was whether MNC could be a cost-effective alternative to COH. In the UMCG IVF centre, based on an evaluation of our MNC cohort (Pelinck et al., 2007) , there is an agreement with local healthcare insurance companies to reimburse a maximum of six MNC cycles instead of the first COH cycle for couples who start IVF or ICSI treatment and in whom female age is ,36 years and there is a proven ovulatory cycle. In order to make a fair comparison between MNC and COH we had to use MNC data from a period when this was offered as the first choice treatment, i.e. [2005] [2006] [2007] [2008] . Moreover, we had to obtain data of COH treatment from another IVF centre, because using the COH patients from the UMCG would have resulted in significant bias; UMCG COH patients are a selected population who have been excluded from MNC because of female age, anovulatory status or because they were offered COH after failed MNC. For this reason we used data of the first COH treatment cycle (SET or DET), including the transfer of cryopreserved embryos, from a comparable patient group from the same period in the Academic Medical Center in Amsterdam (AMC). For both patient groups, we calculated the costs per live birth, for up to six MNC cycles or for one COH cycle with subsequent transfer of cryopreserved embryos, respectively, including costs of IVF treatment and pregnancy up to 6 weeks after delivery. These baseline data were used in three simulated treatment scenarios in which cost-effectiveness of MNC and COH were compared. Scenario 1 was chosen to simulate a situation where the difference in costs between MNC and COH would be reduced. In this scenario the effect of six instead of three cycles of MNC was modelled. Scenario 2 explored the effect of application of strict SET in COH and in scenario 3 minimization of treatment costs in MNC was evaluated.
Materials and Methods

Patients
Data regarding MNC (IVF or ICSI) were extracted from the database of the UMCG, and data on COH (IVF or ICSI) from the AMC. Couples who started their first MNC cycle in the UMCG or their first COH cycle in the AMC between January 2005 and January 2008 were included.
Inclusion criteria for all patients in the UMCG and AMC were: (i) a medical indication for IVF or ICSI; (ii) female age 18-36 years; (ii) first IVF or ICSI treatment ever or first IVF or ICSI treatment after a previous ongoing pregnancy as a result of MNC or COH treatment; (iv) proven ovulatory cycle of 26 -35 days. The extracted data included demographic characteristics, treatment data, such as number of MNC cycles started, amount and type of medication used and number of follicle aspirations and fresh and frozen/ thawed embryo transfers, pregnancy rates and type of pregnancy (singleton or multiple), as well as occurrence of OHSS.
In the Netherlands, no ethical board approval or informed consent from patients is required for retrospective chart review and use of anonymized data.
when the lead follicle reached ≥18 mm diameter. Follicle aspiration was performed 34 h after ovulation triggering. Fertilization of the retrieved oocyte by IVF or ICSI was performed according to standard procedures. Embryo transfer (ET) was performed on the third day after follicle aspiration. Luteal support was provided by administration of 1500 IU hCG s.c. on Days 5, 8 and 11 after follicle aspiration. DET was performed if more than one embryo was available.
COH-IVF was performed using a down-regulation protocol, starting with triptorelin 0.1 mg s.c. (Decapeptyl w , Ferring Nederland BV, Hoofddorp, the Netherlands) daily on the 23rd day of the previous cycle. After a baseline ultrasound, controlled ovarian stimulation was started with 150 or 225 IU r-FSH s.c. daily (Puregon w , Organon, Oss, the Netherlands). Ultrasound monitoring was performed from stimulation day 7 onwards, and the dosage of rFSH was adjusted if necessary. Ovulation was triggered by 10 000 IU hCG s.c. when the leading follicle had reached a diameter of 22 mm. Follicle aspiration was performed 36 h after ovulation triggering. A cycle was cancelled in case of threatening OHSS (E2 levels .15 nmol/l and/or .20 follicles) or poor response (,2 -3 follicles). Fertilization by IVF or ICSI was performed according to standard procedures. SET (elective or compulsory) or DET was carried out on the third day after follicle aspiration depending on embryo quality and availability. Good quality spare embryos were frozen on Day 4 after oocyte collection. Luteal support was provided by 200 mg micronized progesterone administered intravaginally in two daily doses for 2 weeks, starting after oocyte collection.
Cryopreserved embryos were transferred in artificial cycles. On the second day of the menstrual cycle, substitution with E 2 2 mg orally (Progynova w , Bayer, Mijdrecht, The Netherlands) was started at 2 mg twice daily and continued until ultrasound monitoring showed an endometrial thickness of at least 8 mm. Subsequently, micronized progesterone 200 mg was added three times a day and ET was performed 5 days later. Depending on the available number of embryos, SET or DET was performed. Pregnancy was established by an hCG test in serum 2 weeks after ET. In the case of pregnancy, hormonal substitution was continued until 11 weeks of gestation and gradually decreased over a period of 4 days. If no pregnancy occurred all medication was stopped 14 days after ET.
Biochemical pregnancy was defined as a positive pregnancy test in urine or hCG levels .20 IU/l in serum, 14 days after ET. Ongoing pregnancy was defined by the presence of intrauterine embryonic heartbeat on ultrasound examination at 12 weeks of gestation.
For all pregnant patients data regarding the outcome of the pregnancy were collected. Live birth was the primary outcome measure and was defined as the birth of at least one living child after a gestation of at least 25 weeks.
Baseline data
The baseline data for the comparison of MNC versus COH consisted of a maximum of six MNC cycles and one cycle of fresh COH including the subsequent transfer of any cryopreserved embryos, and was based on daily practice in the UMCG for MNC and in the AMC for COH. In the economic evaluation of the baseline data the cost-effectiveness of MNC and COH was assessed from the health-care insurer's perspective with LBR as the primary effect measure. The incremental cost-effectiveness ratio (ICER) was calculated and presented as the difference in costs divided by the difference in LBR, e.g. E 855/2%, expressing the costs per additional live birth. All treatment-related costs, pregnancy-related costs and neonatal costs up to 6 weeks after delivery were included. Because no detailed data were collected for the intake phase of IVF treatment (e.g. intake by a gynaecologist, basic fertility work-up) the costs of this phase were not included. For the COH cycles, no data were available regarding cancellation of cycles before follicle aspiration. Based on data from the Dutch Society for Obstetrics and Gynaecology for 2005 -2007 , [Kremer, www. nvog.nl (14 May 2012, date last accessed)] cancellation rates of 7.6 and 6.6% were applied to the COH-IVF and COH-ICSI cycles, respectively.
Unit costs of items included in the economic evaluation are specified in Table I . Costs of medication were calculated based on actual data on use of medication, and priced according to the 'Farmacotherapeutisch Kompas' (2009), a formulary published by the Dutch Health Insurance Board. Costs of treatment procedures were calculated using fixed Dutch tariffs (2004) for follicular stimulation, follicle aspiration, the laboratory phase and ET. For monitoring and transfer of cryopreserved embryos a separate fixed tariff was used. In case of interrupted treatment cycles, which occurs relatively frequently in MNC, only costs of the completed parts of the cycles were calculated, e.g. only costs of stimulation if follicle aspiration could not be performed. Costs of ongoing pregnancies for singletons and twins were taken from Lukassen et al. (2004) , including costs of pregnancy, delivery and costs up to 6 weeks after delivery, such as maternal hospital admission, neonatal intensive care admission and treatment of complications. Costs of OHSS were based on duration of hospital admission. The unit price for hospital admission days was obtained from the Dutch manual for costing studies (Oostenbrink et al., 2004) . All unit prices were indexed to the price level of 2009. All costs and outcomes were initially calculated at the cycle level and subsequently at the patient level. For an overall comparison of MNC versus COH, IVF and ICSI were combined for both methods.
Simulated treatment scenarios
Three alternative simulated treatment scenarios were constructed to explore the impact of variations of treatment on the cost-effectiveness of MNC versus COH. All alternative scenarios were compared based on ICERs and supported by bootstrap analyses.
Scenario 1 consisted of comparison of the costs and outcomes per patient for a maximum of three cycles MNC instead of six, versus baseline COH data (i.e. SET or DET and subsequent transfer of frozen/thawed embryos).
Scenario 2 entailed a simulation of the rigorous application of SET in all fresh COH cycles and in all subsequent cycles using frozen/thawed embryos versus baseline MNC data. versus DET was assumed to be 0.531, based on a randomized comparative study . All multiple pregnancies in the baseline COH data were converted to singletons and the costs of pregnancy and delivery were reduced accordingly. We performed sensitivity analyses in this scenario assuming alternative values for the relative effectiveness of SET of 60 -75% with 7 -8% increments.
In scenario 3 the impact of a transition from MNC to natural cycle, i.e. IVF without any medication apart from hCG for ovulation triggering, was evaluated. Based on a literature review of 1800 cycles reported in 20 studies (Pelinck et al., 2002 ) the effectiveness of natural cycle IVF expressed as live births per started cycle was assumed to be 8%, which is similar to the LBR of MNC in the baseline data. The costs of medication were set to the price of 10 000 IU hCG.
Cohort size and statistical tests
The size of the MNC cohort was determined by the period during which MNC was offered as standard care in the UMCG, without alterations to the treatment protocol. The COH data were collected during the same period.
Comparisons of pregnancy rates were performed using x 2 test and differences in costs were evaluated using Student's t-test or the Mann-Whitney U-test depending on the distribution of the data. A P-value ,0.05 was considered statistically significant. For all scenarios [ICER (i.e. cost-difference divided by difference in LBR] of MNC versus COH were estimated using bootstrap analysis (Briggs et al., 1997) with 5000 replications (R Core Team (2012) 2012) and the results were plotted in a cost-effectiveness plane. All other statistical analyses were performed using the Statistical Package for the Social Sciences, version 20.
Results
Data from 499 patients who underwent MNC-IVF (n ¼ 247) or MNC-ICSI (n ¼ 252) were available for evaluation. For COH-IVF and COH-ICSI, data from 196 patients for each treatment modality were available. Clinical characteristics of patients are summarized in Table II . For MNC as well as COH, ICSI was performed in younger patients than IVF, who had a shorter median duration of infertility.
The treatment results are presented in Table III . For MNC, patients were offered a maximum of six cycles and underwent an average of 3.9 cycles for IVF and 4.1 cycles for ICSI. For COH only the first fresh cycle was included and the average number of subsequent frozen/ thawed embryo transfers was 0.37 for IVF and 0.48 for ICSI. As a result of differences in cycle completion, the on-going pregnancy rates per cycle were lower for MNC (7.8% for IVF, 11.2% for ICSI) than for COH (31.6% for IVF, 39.8% for ICSI). As expected, the multiple pregnancy rate was lower in MNC (1.8% for IVF, 0% for ICSI) than in fresh COH (15.4% for IVF, 22.2% for ICSI). No multiple pregnancies were observed after transfer of one or two frozen/thawed embryos. The primary outcome measure of at least one live born child differed significantly between treatments at the cycle level, i.e. one MNC (5.0% for IVF, 6.9% for ICSI) versus one COH (18.9% for IVF, 26.5% for ICSI, P , 0.001), but at the patient level, i.e. up to six MNC versus one COH plus cryo transfers (i.e. frozen/thawed ET), outcome did not differ significantly [21.9% (IVF) and 26.2% (ICSI) for MNC versus 21.9% (IVF) and 32.1% (ICSI) for COH, P ¼ 0.054]. The incidence of OHSS in COH-ICSI was about twice as high as in COH-IVF (4.6 versus 2.0%, respectively), and resulted in more admissions and more admission days. Almost half of the admission days were caused by one patient who was hospitalized for 27 days.
Average costs per treatment cycle are summarized in Table IV . On a per cycle basis, costs of medication were about four times lower for MNC than for COH [E206.4 (IVF) and E207.7 (ICSI) for MNC versus E979.8 (IVF) and E1015.3 (ICSI) for COH]. This was mainly caused by shorter duration of administration of r-FSH. Costs of pregnancies and deliveries reflected the differences in pregnancy rates and the lower percentage of twin pregnancies in MNC. As a result, total average treatment costs per cycle of MNC including pregnancy and delivery were two to three times lower than for one fresh COH cycle [E1297.6 (IVF) and E1330.9 (ICSI) for MNC versus E2908.2 (IVF) and E3538. Cost-effectiveness of different IVF treatments costs at the level of the patient showed that total costs of up to six cycles of MNC per patient were significantly higher than for one cycle of COH [E5415.5 (IVF) and E5096.4 (ICSI) for MNC versus E3221.6 (IVF) and E4166.5 (ICSI) for COH] resulting in higher costs per live birth for MNC than for COH.
The results of the baseline data, aggregated for MNC and COH treatments, irrespective of whether IVF or ICSI was performed, are shown in Table V . In addition, the results of the three scenarios are shown, but only if they differ from baseline. The average costs and live birth rate (LBR) per patient in each of the scenarios provided the input for the bootstrap analyses are presented in Fig. 1 . In the baseline comparison, six cycles of MNC was unfavourable with respect to costs per patient and LBR compared with one cycle of COH: MNC was more expensive (E5254.3 versus E3694.4) and less effective (LBR 24.0 versus 27.0%), making COH the dominant strategy (ICER: E1604/23%). Simulated reduction of the number of MNC cycles to three, as applied in scenario 1, resulted in approximately equal costs per patient as in one cycle of COH (E3389.7 for MNC versus E3694.4 for COH) but also in considerable loss of effectiveness (LBR 16.2% for MNC versus 27.0% for COH, ICER: E2224/210.8%). Strict application of SET in fresh COH and cryo transfer cycles (scenario 2) resulted in a clear shift in effectiveness in favour of six cycles of MNC (17.5% for COH versus 24.0% for MNC), while costs of COH were still lower than costs of MNC (E2908.3 versus E5254.3). Compared with the baseline data, the cost difference between MNC and COH increased, mainly due to lower costs of pregnancy and childbirth in COH due to the prevention of multiple pregnancies (ICER: E2753/6.6%). Sensitivity analyses showed improved cost-effectiveness with increasing relative effectiveness of SET: E15 577 per live birth at 60% relative effectiveness (overall LBR 18.9%), E14 674 per live birth at 67% (LBR 20.3%) and E13 790 per live birth at 75% (LBR 21.9%). The third scenario showed that less medication use in MNC reduced the cost difference with COH by E785 (E4469.4 versus E3694.4) while the difference in effectiveness (24.0 versus 27.0%) was not influenced as per our underlying assumption that reduced medication would not affect LBR (ICER: E855/23%).
Discussion
In this study we evaluated the cost-effectiveness of MNC versus COH in three simulated scenarios comparing different treatment regimens. The baseline data used in these scenarios consisted of a retrospective evaluation of treatment characteristics, outcomes and costs for MNC and COH over a 3-year period in two Dutch IVF centres. Our results showed that MNC was not cost-effective in the baseline comparison (i.e. up to six MNC cycles versus one fresh COH cycle with SET or DET with subsequent use of frozen/thawed embryos). treatment scenarios with strict application of SET in COH (scenario 2), assuming considerable loss of effectiveness in terms of LBR by strict SET instead of mixed DET and SET, had the largest impact on the incremental cost-effectiveness of MNC versus COH, decreasing the LBR of COH to below the level of MNC. Costs of MNC in this scenario were still higher than for COH. The scenario with minimization of medication use in MNC (scenario 3) improved cost-effectiveness of MNC. Reduction from six to three cycles of MNC (scenario 1) caused a considerable decrease in costs but did not improve the position of MNC versus COH. The combined results of scenarios 2 and 3 suggest that MNC with minimized medication might be a cost-effective alternative for COH with strict SET. In daily practice, treatment choices have to be made based on individual characteristics of the infertile couple and their preferences. In this choice a balance has to be struck between effectiveness in terms of LBR, risks and burden of treatment. In addition, treatment costs have to be taken into account since governments and decision-makers require reductions in reimbursement from national health-care budgets and a higher financial contribution by the patients. Both the direct treatment costs as well as costs related to maternal and neonatal complications contribute to the economic burden of IVF, particularly in high-risk multiple pregnancies. The societal burden of IVF includes indirect and less visible costs as well, such as those of travel and work absence during treatment and delivery.
As a result, effectiveness may have to be sacrificed to a certain degree, in exchange for safer treatment with fewer side effects or reduced costs. The discussion about optimal outcome of IVF treatment has resulted in the definition of a healthy live born child as 'BESST' outcome (Bhattacharya and Templeton 2004; Davies et al., 2004; Heijnen et al., 2004; Land and Evers 2004; Min et al., 2004; Pinborg et al., 2004; Tiitinen et al., 2004) , and prevention of costly multiple pregnancies by performing strict SET. Further measures include the use of low-cost medication and reducing the amount of medication by use of milder stimulation, ranging from mild hyperstimulation to natural cycles with minimal or no medication. Many alternatives are conceivable and it is not feasible to investigate all of these in clinical trials. Therefore, we analysed three plausible treatment scenarios to evaluate the potential of MNC as a cost-effective alternative for COH. The scenarios were designed to include COH with and without SET, different numbers of MNC treatment cycles and variations of medication costs. They mirror the changes in regulations and guidelines that have been implemented in several European countries regarding the use of COH with SET and preferences towards less aggressive treatments.
Strengths of the study
Because only results obtained in the first treatment episodes were used for patients in similar age groups, selection bias was largely prevented. 
Cost-effectiveness of different IVF treatments
The cost-effectiveness analysis was based on direct medical costs, including costs of IVF treatment, pregnancy, childbirth and OHSS. Apart from costs of medication, avoidable costs mainly consist of costs of OHSS and multiple pregnancies, which can both be considered as complications of COH treatment. In our study OHSS occurred in 13 of 392 fresh COH cycles (3.3%), which corresponds with the literature, reporting clinically significant OHSS in 3-5% of cycles (Heijnen et al., 2006) . In our study the rate of twin pregnancies in COH was 18.3%, slightly lower than in European Society of Human Reproduction and Embryology (ESHRE) data of 2008 which showed 21.7% multiple (twin or higher order) pregnancies (Ferraretti et al., 2012) . Using the ESHRE estimate for our baseline comparison would have negatively affected the cost-effectiveness of COH, because of the high costs of twin pregnancies. Our evaluation includes the direct medical costs of pregnancies until 6 weeks postpartum, including maternal hospital admission, neonatal intensive care admission and treatment of complications. This perspective ignores societal costs and long-term costs associated with lifelong disabilities, such as cerebral palsy, for which twin children are at increased risk (Henderson et al., 2004; Hack 2006) . Data from the literature suggest that such lifetime costs may be as high as $100 000-$500 000 (Centers for Disease Control 1995; Venditti et al., 2003) . The magnitude of these long-term costs stresses the importance of the implementation of strategies to prevent twin pregnancies.
Weaknesses of the study
Our study has some limitations which are inherent to the retrospective study design. First, we performed our comparison in women ,36 years of age because this was the age limit for patients who were offered MNC. In ESHRE data, 15% of IVF patients are 40 years or older, and our results cannot be extrapolated to this subgroup (Ferraretti et al., 2012) . Moreover, MNC is only suitable for ovulatory patients. The retrospective nature of our study also precluded an evaluation from the societal perspective, which would have required additional data, such as leave or absence from work and travel costs. Finally, our baseline data originated from the years 2005-2008 because MNC was offered as firstchoice treatment during this period. Current LBRs for COH are significantly higher, but a comparison of the results from the centre that provided the COH data with the average results in the Netherlands at that time showed that the results were representative.
Our baseline data confirmed the impact of the cost of medication on the total costs of IVF treatment. For MNC, medication costs on average represented 15% of total costs per cycle. For COH, 25-30% of total costs were spent on medication. Our estimates correspond to those in the literature, reporting that the costs of medication mainly depend on price of r-FSH-preparations, and that costs of GnRH agonists and antagonists play a minor role (Polinder et al., 2008) . Changes in the medication regimen, for example milder stimulation, may have a major impact on the cost-effectiveness of COH. In a direct randomized comparison of mild IVF combined with SET versus standard IVF combined with DET, a significant cost reduction was observed (E8.333 versus E10.745 per patients, respectively) with cumulative term LBRs over 1 year of 43.4 versus 44.7%, respectively (Polinder et al., 2008) . Recombinant FSH is widely used in IVF, although its superiority over urinary FSH in terms of LBR has not been demonstrated (van Wely et al., 2012) . Given the large contribution of r-FSH to the medication costs, the use of less expensive urinary products or biosimilars in the near future, especially in combination with mild stimulation, will have a considerable impact on costs of COH and will not improve the cost-effectiveness of MNC versus COH. On the other hand, scenario 3 with reduced medication in MNC indicated that substantial costs in MNC can be reduced. However, the effectiveness of natural cycle IVF without medication has not been widely studied, and we used the estimated effectiveness based on a review of the literature.
MNC is less expensive than COH, but also less effective. Therefore, in the UMCG, health-care insurers have agreed to reimburse six cycles of MNC instead of one (i.e. the first) COH cycle. This policy is based on a previous study in which we showed that in up to six MNC cycles cumulative pregnancy rates and LBRs are comparable to those obtained in one COH cycle (Pelinck et al., 2004) . The results of the baseline analysis in the present study have confirmed these previous findings. Less than six MNC cycles have been shown to be less effective (Pelinck et al., 2004) , as was confirmed in scenario 1 with three MNC cycles. More than six cycles could increase cumulative pregnancy rates but at higher costs. Although pregnancy rates per cycle after the sixth MNC cycle remain stable, increased dropout rates from the sixth cycle onwards cause the cumulative pregnancy rate per patient to diminish (Pelinck et al., 2007) . Although MNC is considered a low-burden treatment, patient preference still needs to be evaluated.
In our scenario with strict SET, twin pregnancies were completely eliminated. The positive effect on the costs of pregnancies was completely counteracted by the considerable loss of effectiveness that resulted in this strategy, as found in a randomized comparison of SET versus DET (pregnancy rates 21.4 versus 40.3%, respectively) . In the present study, additional pregnancies from cryopreserved embryos were not taken into account. Since strict SET may result in more spare embryos for cryopreservation, the lower pregnancy rates after transfer of fresh embryos may be partially compensated in case of improvement of cryopreservation techniques and additional pregnancies from frozen/thawed ETs. Our SET scenario did not take into account the increase in availability of embryos for cryopreservation and subsequent transfer. If we assume that 50 -100% of surplus embryos could be cryopreserved and transferred later, in scenario 2 the LBR per patient in COH might increase to 19-20%. But even then, the LBR in MNC would still be superior to COH with strict SET. Our sensitivity analyses for scenario 2 indicate that effectiveness of COH with strict SET would have to be 75% or higher in order to be as cost-effective as the baseline COH strategy with mixed SET and DET treatments. The results of these sensitivity analyses can also be regarded as an indication of the impact of higher baseline LBRs for COH, as might be anticipated with improved treatment methods.
In conclusion, there is a need for further evaluation of costeffectiveness of different fertility treatment modalities. Many alternatives are conceivable and it is not feasible to investigate all of these in clinical trials. Therefore, we analysed three plausible treatment scenarios to evaluate the potential of MNC as a cost-effective alternative for COH. Our baseline comparison of six cycles MNC versus one cycle COH with SET or DET with subsequent transfer of cryopreserved embryos shows that MNC is not cost-effective in this setting. Our comparison of three simulated scenarios, reflecting realistic alternatives in daily practice, indicates that a treatment strategy with three to six cycles of MNC with minimization of medication is a cost-effective alternative for one cycle of COH with strict application of SET. The choice for MNC as a preferential treatment depends on the willingness to trade off effectiveness against the benefits of a milder stimulation regimen with a very low rate of multiple pregnancies and OHSS, and ensuing lower costs per pregnancy. Complementary data will be provided by a randomized comparison of MNC, intrauterine insemination and COH-SET in couples with unexplained infertility (Bensdorp et al., 2009) . This study will contribute to the continued consideration of cost-effectiveness of fertility treatment. 
Funding
The study was supported by research grants from Merck Serono and Ferring Pharmaceuticals.
